Previous studies revealed that the increased plasma GPC1 + exosomes as well as decreased miR-96-5p and miR-149 were biomarkers for the diagnosis of CRC and a potential therapy target especially for stage III CRC [38, 39]. This evidence concerns the gene GPC1 and colorectal carcinoma.